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In this report, we describe a case of an 18-year-old woman
with massive septal hypertrophic cardiomyopathy (HCM)
without left ventricular outﬂow tract (LVOT) obstruction
that was discovered after resuscitation from a witnessed
cardiac arrest. HCM is the most common genetic cardiomy-
opathy, with an incidence of 0.2%.1 It is associated with a
1% annual rate of sudden cardiac death (SCD).2 Septal
myectomy, typically reserved for treatment of LVOT, has
not previously been described in the literature as a means to
debulk the substrate for recurrent ventricular arrhythmias.
Case report
The patient is an 18-year-old woman with no signiﬁcant
prior medical history. While dancing, she experienced a
witnessed collapse and was found pulseless. Immediate
cardiopulmonary resuscitation was started, and spontane-
ous circulation returned after 2 minutes. A deﬁbrillator was
not readily available, and therefore the presenting cardiac
rhythm was unknown. The patient was subsequently trans-
ferred to a tertiary care hospital, where she denied experi-
encing any prodrome of presyncope, palpitations, or chest
pain prior to the cardiac arrest. She did reveal a familyKEYWORDS Hypertrophic cardiomyopathy; Ventricular arrhythmia; Septal
myectomy; Sudden cardiac death; Myocardial bridging
ABBREVIATIONS HCM ¼ hypertrophic cardiomyopathy; ICD ¼
implantable cardioverter-defibrillator; LVOT ¼ left ventricular outflow
tract; SCD¼ sudden cardiac death; TTE¼ transthoracic echocardiogram;
VATS ¼ video-assisted thoracoscopic surgery; VT ¼ ventricular
tachycardia (Heart Rhythm Case Reports 2015;1:300–304)
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).history of sudden death in a maternal aunt and a heart
transplant in a maternal uncle at age 19, but no further
details were available.
On admission, she was alert and oriented and in no acute
distress. Physical exam ﬁndings were unremarkable. Basic
complete blood count and electrolyte studies were within
normal limits. An initial electrocardiogram demonstrated left
ventricular hypertrophy with ST depression and T-wave
inversion in the anterolateral leads (Figure 1). A trans-
thoracic echocardiogram demonstrated marked asymmetrical
ventriculoseptal hypertrophy of 29 mm, consistent with the
reverse-curve subtype of HCM (Figure 2A). There was no
evidence of systolic motion of the anterior mitral valve or
evidence of an outﬂow tract obstruction by continuous wave
Doppler echocardiogram (Figure 2B). The patient’s familial
history of sudden cardiac death (SCD) predisposed her to an
increased risk of recurrent malignant ventricular arrhyth-
mias,3 and therefore a single-chamber implantable
cardioverter-deﬁbrillator (ICD) was implanted prior to dis-
charge and metoprolol tartrate 25 mg twice daily was started.
Of note, the metoprolol could not be further titrated because
of the development of symptomatic bradycardia.
Unfortunately, the patient returned 5 months later follow-
ing 4 events of ventricular ﬁbrillation with successful ICD
deﬁbrillation occurring during moderate exertion. A tread-
mill echocardiographic (ECG) stress test precipitated syn-
cope due to polymorphic ventricular tachycardia (Figure 4).
She ultimately received cardiopulmonary resuscitation with
restoration of sinus rhythm after 1 ICD deﬁbrillation therapy.
The patient denied experiencing any angina or presyncope
prior to this event. A subsequent electrophysiological study
did not demonstrate an inducible monomorphic ventricular
tachycardia or appreciable trigger for polymorphic ventric-
ular tachycardia or ventricular ﬁbrillation. She was started on
sotalol 120 mg twice daily, and because of bradycardia, the
metoprolol was discontinued. She subsequently underwent a
left-sided video-assisted thoracoscopic surgery (VATS)
sympathectomy. On her recovery from surgery, a repeatpen access article under the CC BY-NC-ND license
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KEY TEACHING POINTS
 Septal myectomy may be an effective treatment for
ischemia-induced ventricular arrhythmia in
hypertrophic cardiomyopathy (HCM) patients.
 Coronary ischemia due to myocardial bridging is a
potentially reversible and possibly underrecognized
cause of ventricular arrhythmias in HCM patients.
 Septal myectomy is a mainstay of treatment for
symptomatic left ventricular outﬂow tract
obstruction refractory to medical therapy.
301Sun et al Septal Bridge and Ventricular Fibrillationtreadmill ECG stress test was performed. At 1 minute
50 seconds into stage 1 of a Bruce protocol, ST depression
in the anterior, anterolateral and inferior leads with ST
elevation in AVR (Figure 3) was noted. A few seconds later,
polymorphic ventricular tachycardia developed (Figure 4)
that degenerated into ventricular ﬁbrillation that was termi-
nated by ICD shock delivery.
Because of the recurrent polymorphic ventricular tachy-
cardia preceded by the ST changes that were concerning for
ischemia, a coronary angiogram was performed. Results
showed no coronary atherosclerosis but revealed marked
myocardial bridging of large ﬁrst and second septal perfo-
rators (Figures 5A and 5B). It was suspected that the
patient’s polymorphic ventricular tachycardia (VT) was
mediated by an exertional increase in myocardial contrac-
tility exacerbating myocardial bridging, with resultant ische-
mia and polymorphic VT. Accordingly, a septal myectomy
was scheduled with the intention to debulk the interven-
tricular septum in hopes to decrease ischemia and thereby
remove the arrhythmogenic substrate.
The septal myectomy was successfully performed with an
approach through the aorta and the left ventricular apex toFigure 1 A 12-lead resting electrocardiogram demonstrating increased voltage
and T-wave inversion consistent with hypertrophic cardiomyopathy.optimize exposure. Cardiac bypass was commenced and the
aorta was cross-clamped. Then, an oblique aortotomy was
performed, and the aortic cusps were retracted, allowing
exposure to the subaortic septum. An extended septal
myectomy was performed to the level of the papillary
muscles with sparing of the septal perforators After closure
of the aortotomy, an apical ventriculotomy was performed,
followed by a wide excision of the septum until it joined the
area of the subaortic excision. The removed tissue demon-
strated moderate to marked myocyte hypertrophy with mild
to focally moderate interstitial ﬁbrosis with no evidence of
endocardial ﬁbrosis. Lastly, the ventriculotomy was closed
with 2 layers of running sutures. The cross-clamp was
released, and temporary extracorporeal circulation was
successfully discontinued. The total aortic cross-clamp
duration was 27 minutes, and estimated blood loss was
o250 cm3. The patient successfully recovered and was
discharged from the hospital 6 days postoperatively with the
recommendation to continue sotalol therapy. Electroana-
tomic mapping done 4 months after myectomy showed
evidence of septal scar on myocardium. A year and a half
post myectomy, the patient had no recurrent ventricular
arrhythmias. She had a follow-up ECG cardiac stress test that
did not provoke ventricular arrhythmias.Discussion
HCM is the most common genetic cardiomyopathy, with an
incidence of 0.2%.1 Among the population of HCM patients,
the annual incidence of SCD is approximately 1%.2 Of
several precipitating factors for SCD previously identiﬁed,3
the patient demonstrated 3: prior history of SCD, sponta-
neous ventricular tachycardia, and a presumed family history
of SCD due to HCM.
ECG stress testing is reasonable to consider in HCM to
determine response to therapy aimed at relieving outﬂowconsistent with left ventricular hypertrophy and anterolateral ST depression
Figure 2 A: Parasternal long-axis transthoracic echocardiogram demonstrating marked septal hypertrophy (29 mm) and reverse-curve morphology. B:
Continuous wave Doppler echocardiogram through the left ventricular outﬂow tract in the apical long-axis view without evidence of obstruction (highest
recorded gradient was 0.8 m/s).
Heart Rhythm Case Reports, Vol 1, No 5, September 2015302tract obstruction, systolic anterior motion of the mitral
valve, and mitral regurgitation (Class IIa).3 In the current
case, repeat ECG treadmill testing was performed
to determine if either pharmacotherapy or VATS would
be successful in precluding recurrent ventricular arrhyth-
mias. Typically, the development of ventricular tachy-
cardia in HCM stress testing is rare: in a prior series ofFigure 3 Echocardiogram stress test results revealing pronounced ST depression
These ﬁndings developed 1 minute 50 seconds into a Bruce-protocol stress test an43000 patients, only 1 (0.03%) had developed ventri-
cular tachycardia.4 However, in the current case, exer-
tional polymorphic ventricular tachycardia did occur,
underscoring the importance to rule out structural
cause for an ischemic trigger such as coronary athero-
sclerosis, myocardial bridging, or an anomalous coronary
artery.s in the anterior, anterolateral, and inferior leads with ST elevation in AVR.
d were concerning for ischemia.
Figure 4 Echocardiogram stress test results revealing polymorphic ventricular tachycardia that developed 4 minutes 6 seconds into a Bruce-protocol stress test
(2 minutes 16 seconds after the ST changes described in Figure 3 occurred).
303Sun et al Septal Bridge and Ventricular FibrillationPharmacotherapies including beta blockers and antiar-
rhythmic agents should not be used in lieu of ICD when ICD
is indicated. In the current case, sotalol therapy was started in
an attempt to preclude recurrent ventricular arrhythmias that
were inciting ICD tachyarrhythmia therapies. A small,
double-blind, crossover study has demonstrated the effec-
tiveness of sotalol in suppression of ventricular arrhythmiasFigure 5 A: Coronary angiogram demonstrating a large septal perforator (red ain patients with HCM.5 In the study, 54 percent of patients
experiencing ventricular arrhythmias on placebo had reso-
lution of these arrhythmias when sotalol therapy was started
(P o .05). Moreover, this same study population improved
the ECG stress test duration by 1 minute (P o .01). In the
current case, another option to be considered would be beta-
blockade titration as a means to reduce myocardial bridging.rrow). B: During systole, marked myocardial bridging is noted (blue arrow).
Heart Rhythm Case Reports, Vol 1, No 5, September 2015304However, the patient developed bradycardia with low doses
of metoprolol therapy, inhibiting further titration.
A left VATS sympathectomy decreases noradrenergic
stimulation of the left ventricle by removing portions of the
left stellate and thoracic ganglia. Prior experiences in the
HCM population have demonstrated variable response to
sympathectomy, with some patients having complete remis-
sion and others having persistent arrhythmias.6 Unfortu-
nately, in the current case, left-sided sympathectomy did not
prove successful. Consideration of a bilateral sympathec-
tomy would have subjected the patient to the risks of
intervention, including the development of Horner syndrome
as well as a pneumothorax, without any evidence of beneﬁt.
Electrophysiological ablation has been demonstrated to
successfully treat recurrent monomorphic ventricular
arrhythmias in the HCM population7 and can be considered
to eliminate ventricular ectopy known to trigger polymorphic
ventricular tachycardia or ventricular ﬁbrillation.8 However,
in the current case, the patient had no inducible monomor-
phic ventricular arrhythmias or appreciable triggers for
polymorphic ventricular tachycardia or ventricular ﬁbrilla-
tion during electrophysiological testing, suggesting that the
unrooﬁng of the myocardial bridges and debulking ischemic
substrate by myectomy were the main mechanisms for
eliminating the arrhythmia. Cardiac transplant for incessant
ventricular arrhythmias in the HCM population may also be
considered.9
However, given the patient’s young age at presentation,
an innovative approach was chosen in an attempt to avoid the
long-term morbidity associated with cardiac transplantation.
Coronary stenting of the septal perforators to inhibit bridging
was not attempted, given evidence of prior trials suggesting
increased rates of postintervention in-stent stenosis.10 Com-
pared with septal myectomy, alcohol septal ablation would
be limited in its capability to debulk the myocardium.
Moreover, septal ablation would induce ischemia and pre-
dispose the patient to further ventricular arrhythmias.11
Therefore, septal myectomy was the chosen intervention.
Although septal myectomy has proven to be a mainstay of
treatment for symptomatic left ventricular outﬂow tract
obstruction that is refractory to medical therapy,12 its use
to successfully debulk an arrhythmogenic substrate in non-
obstructive HCM is novel.
Conclusion
HCM is a common cardiomyopathy and may be associated
with life-threatening ventricular arrhythmias necessitating
ICD implantation. Invasive procedures, such as septal
ablation or septal myectomy, are typically reserved for
treatment of symptomatic LVOT. Treatments for ventri-
cular arrhythmias include ICD implantation for primary or
secondary prevention,3 beta-blockade, antiarrhythmics, andVATS. In refractory cases, cardiac transplantation may be
considered.
The current case describes a rare phenomenon of
exercise-induced ventricular arrhythmia in a patient with
HCM. Moreover, prior to the development of polymorphic
ventricular tachycardia, the echocardiogram demonstrated
changes consistent with ischemia. Therefore, the presence of
polymorphic ventricular tachycardia in patients with HCM
may be a clue to a potentially reversible and possibly
underrecognized cause for ventricular arrhythmias, such as
coronary ischemia due to myocardial bridging. In the current
case, a coronary angiogram was negative for atherosclerosis
but did show marked bridging of large ﬁrst and second septal
perforators. Extended septal myectomy successfully pre-
cluded any recurrent arrhythmias. This case describes the
novel use of ventricular myectomy to debulk ischemic
substrate in HCM to prevent recurrent arrhythmias.
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